Cardiovascular Disease
From challenges to clearer pathways
Cardiovascular Disease
From challenges to clearer pathways

Supplement Editor
Maan A. Fares, MD
Heart, Vascular, and Thoracic Institute
Cleveland Clinic

Table of Contents

4 Functional tricuspid regurgitation: Feasibility of transcatheter interventions
Vinayak Nagaraja, MD; Divyanshu Mohananey, MD; Jose Navia, MD; Serge C. Harb, MD; Rhonda Miyasaka, MD; Amar Krishnaswamy, MD; and Samir Kapadia, MD

15 A practical approach to the cholesterol guidelines and ASCVD prevention
Leslie Cho, MD

21 New treatments for peripheral artery disease
John Bartholomew, MD, and G. Jay Bishop, MD

From the editor
Despite advances in percutaneous interventions for many valve diseases, treatments for the tricuspid valve remain elusive. In this Cleveland Clinic Journal of Medicine supplement, Samir Kapadia, MD, and colleagues describe innovations in percutaneous techniques that may overcome the challenges associated with tricuspid valve repair.

Many cardiologists and primary care physicians struggle to keep current with the constantly changing practice guidelines for the prevention of atherosclerotic cardiovascular disease. Cutting through the complexity of the latest guidelines, Leslie Cho, MD, manages to clarify them in a way that is easy to understand and implement in practice.

Finally, John R. Bartholomew, MD, reviews the latest treatment guidelines for peripheral artery disease (PAD), a common, potentially morbid vascular disease. PAD is often asymptomatic and often overlooked. A simple diagnostic test and treatment is warranted to reduce the risk of adverse cardiovascular events and limb events associated with PAD.

We hope this Cleveland Clinic Journal of Medicine cardiovascular supplement is useful to you in your clinical practice.

Maan A. Fares, MD
Functional tricuspid regurgitation: Feasibility of transcatheter interventions

**ABSTRACT**

Functional tricuspid regurgitation (TR) develops secondary to annular dilation and leaflet tethering as a result of right ventricular remodeling. Invasive surgery for isolated TR is rarely performed due to high inpatient mortality. Transcatheter tricuspid valve intervention is an appealing solution but is challenging as crucial structures are closely related to the tricuspid valve, and intracardiac devices pose further challenges to device delivery and implantation.

**KEY POINTS**

- Preprocedural multimodality imaging is essential to identify the appropriate device and to ensure procedural success.
- Transcatheter tricuspid valve devices can be classified based on the mechanism of action.
- To date, the MitraClip in the tricuspid position (TriClip) is the most utilized device for tricuspid valve repair. Modifications to the TriClip and Pascal device may improve applicability and outcomes.
- Transcatheter tricuspid valve interventions appear to be associated with improvement in patient quality of life.

**INTRODUCTION**

Primary tricuspid regurgitation (TR) occurs as a result of an anatomically abnormal tricuspid valve. Trace or mild TR is common even in anatomically normally looking valves and has no pathological implications. Certain etiologies such as rheumatic heart disease, prolapse, congenital disease (Ebstein anomaly), infective endocarditis, blunt wall trauma, endomyocardial biopsy-related trauma, and intra-annular right ventricular (RV) pacemaker or implantable cardiac defibrillator leads may result in more significant primary TR. However, it is important to note that close to 80% of TR cases are “functional” rather than primary.

Functional TR occurs secondary to annular dilation and leaflet tethering as a result of RV remodeling from either volume or pressure overload. The prevalence of functional TR in the United States is 1.6 million. Such RV remodeling and resulting TR frequently occur as a complication of left-sided valvular disease, with mitral valve disease being the most common culprit. Severe TR is associated with poor prognosis independent of age and biventricular function. Early studies in the 1960s suggested that treatment of left-sided valvular pathology (particularly mitral) may reverse pulmonary hypertension and therefore TR. However, more contemporary literature reveals that this process is gradual and often unpredictable.

Currently, surgical techniques are the mainstay of treatment for progressive or severe functional TR. However, with the advent and success of transcatheter...
eter techniques for severe aortic stenosis and mitral regurgitation, there is newfound interest in creating safe and effective methods for minimally invasive management of functional TR.

**ANATOMY, PATHOPHYSIOLOGY**

Located between the right atrium and the RV, the tricuspid valve is slightly more apical than the mitral valve and consists of an annulus, leaflets, papillary muscles, and chordae tendinae (Figure 1).7

The tricuspid valve is oriented at a 45-degree angle to the sagittal plane facing anterolaterally and inferiorly toward the left side. The annulus of the tricuspid valve is a nonplanar structure with a distinct bimodal or saddle-shaped pattern having 2 high points (oriented superiorly toward the right atrium) and 2 low points (oriented inferiorly toward the RV). The tricuspid annular area on 3-dimensional (3D) echocardiography has been estimated as 9.72 ± 2.08 cm² in normal individuals. RV or annular dilation and tethering of the leaflets are the 2 main pathophysiologic mechanisms for the development of functional TR. While this is mostly secondary to left-sided disease, it may also be associated with isolated RV disease or pulmonary hypertension. The TR that develops through these mechanisms leads to further RV dilation and dysfunction and more tricuspid annular dilation and tethering, thereby progressively worsening the existing TR. This vicious cycle perpetuates TR and forms an integral part of the pathophysiology of severe TR. The increase in right-sided volumes and pressures impedes left ventricular relaxation and ejection, with resultant diastolic and sometimes systolic dysfunction.8,9

Anatomically, in patients with functional TR, the annulus is larger, flatter, and more circular thereby altering the saddle shape of a normal valve. The dilation of the tricuspid valve is oriented at a 45-degree angle to the sagittal plane facing anterolaterally and inferiorly toward the left side. The annulus of the tricuspid valve is a nonplanar structure with a distinct bimodal or saddle-shaped pattern having 2 high points (oriented superiorly toward the right atrium) and 2 low points (oriented inferiorly toward the RV). The tricuspid annular area on 3-dimensional (3D) echocardiography has been estimated as 9.72 ± 2.08 cm² in normal individuals. RV or annular dilation and tethering of the leaflets are the 2 main pathophysiologic mechanisms for the development of functional TR. While this is mostly secondary to left-sided disease, it may also be associated with isolated RV disease or pulmonary hypertension. The TR that develops through these mechanisms leads to further RV dilation and dysfunction and more tricuspid annular dilation and tethering, thereby progressively worsening the existing TR. This vicious cycle perpetuates TR and forms an integral part of the pathophysiology of severe TR. The increase in right-sided volumes and pressures impedes left ventricular relaxation and ejection, with resultant diastolic and sometimes systolic dysfunction.

Anatomically, in patients with functional TR, the annulus is larger, flatter, and more circular thereby altering the saddle shape of a normal valve. The dilation of the tricuspid valve is oriented at a 45-degree angle to the sagittal plane facing anterolaterally and inferiorly toward the left side. The annulus of the tricuspid valve is a nonplanar structure with a distinct bimodal or saddle-shaped pattern having 2 high points (oriented superiorly toward the right atrium) and 2 low points (oriented inferiorly toward the RV). The tricuspid annular area on 3-dimensional (3D) echocardiography has been estimated as 9.72 ± 2.08 cm² in normal individuals. RV or annular dilation and tethering of the leaflets are the 2 main pathophysiologic mechanisms for the development of functional TR. While this is mostly secondary to left-sided disease, it may also be associated with isolated RV disease or pulmonary hypertension. The TR that develops through these mechanisms leads to further RV dilation and dysfunction and more tricuspid annular dilation and tethering, thereby progressively worsening the existing TR. This vicious cycle perpetuates TR and forms an integral part of the pathophysiology of severe TR. The increase in right-sided volumes and pressures impedes left ventricular relaxation and ejection, with resultant diastolic and sometimes systolic dysfunction.

[Figure 2. (A–C) Transthoracic echocardiography (TTE) views and (D–F) transesophageal echocardiography (TEE) views of the tricuspid valve (TV). (A) TTE 4-chamber view: The septal leaflet is shown in red. The other leaflet (orange) could be the anterior leaflet (if probe is angled anteriorly and the aortic valve is brought into view, ie, 5-chamber view) or the posterior leaflet (if probe is angled posteriorly and coronary sinus brought into view). (B) TTE RV infl ow view: The anterior leaflet is shown in blue. The other leaflet (in green) could be the posterior leaflet or the septal leaflet. (C) TTE 3D focused on the tricuspid valve. Three orthogonal planes centered on the TV are cross-referenced (inlets on the left), allowing easier identification of the different leaflets. (D) TEE 4-chamber view: As in the TTE 4-chamber view, the septal leaflet (in red) is identified, and the other leaflet (orange) could be either the anterior or posterior. (E) TEE RV infl ow view: The posterior leaflet is shown in purple, the other leaflet (in grey) could be either the anterior or septal leaflet. (F) TEE 3D focused on the tricuspid valve. As in the 3D TTE, 3 orthogonal planes are cross-referenced. The different leaflets are easier to identify.

Figure 3. (A and B) Steady-state free precession magnetic resonance images in a 4-chamber and short-axis orientation, respectively. (A) Severely dilated tricuspid annulus (double arrow in yellow). The arrow in D points to a large area of central regurgitation (flow dephasing) caused by a lack of leaflet coaptation secondary to severe annular dilation. (C) Corresponding computed tomography image in a 4-chamber orientation also demonstrating an enlarged annulus (double arrow in yellow). The annular enlargement is better appreciated on the short-axis view (D, blue arrows).]
Although this staging scheme implies linear progression of the disease, in fact there may be patients with little tethering and RV remodeling but with severe TR secondary to severe right atrial dilatation, such as patients with idiopathic functional tricuspid regurgitation.

Consider exercise test to evaluate functional capacity objectively.

Multidisciplinary evaluation may be needed.

EFS = early feasibility studies; IDE = investigational device exemption; IV = intravenous; RCT = randomized controlled trial; RHF = right heart failure; RV = right ventricular; TR = tricuspid regurgitation; TV = tricuspid valve; TVR = tricuspid valve replacement

Source: Repinted with permission from Latib A, Grigioni F, Hahn RT. Tricuspid regurgitation: what is the real clinical impact and how often should it be treated? EuroIntervention 2018;14(AB):AB101–AB111.

Although this staging scheme implies linear progression of the disease, in fact there may be patients with little tethering and RV remodeling but with severe TR secondary to severe right atrial dilatation, such as patients with idiopathic functional tricuspid regurgitation.

Consider exercise test to evaluate functional capacity objectively.

Multidisciplinary evaluation may be needed.

EFS = early feasibility studies; IDE = investigational device exemption; IV = intravenous; RCT = randomized controlled trial; RHF = right heart failure; RV = right ventricular; TR = tricuspid regurgitation; TV = tricuspid valve; TVR = tricuspid valve replacement

Source: Repinted with permission from Latib A, Grigioni F, Hahn RT. Tricuspid regurgitation: what is the real clinical impact and how often should it be treated? EuroIntervention 2018;14(AB):AB101–AB111.

Although this staging scheme implies linear progression of the disease, in fact there may be patients with little tethering and RV remodeling but with severe TR secondary to severe right atrial dilatation, such as patients with idiopathic functional tricuspid regurgitation.

Consider exercise test to evaluate functional capacity objectively.

Multidisciplinary evaluation may be needed.

EFS = early feasibility studies; IDE = investigational device exemption; IV = intravenous; RCT = randomized controlled trial; RHF = right heart failure; RV = right ventricular; TR = tricuspid regurgitation; TV = tricuspid valve; TVR = tricuspid valve replacement

Source: Repinted with permission from Latib A, Grigioni F, Hahn RT. Tricuspid regurgitation: what is the real clinical impact and how often should it be treated? EuroIntervention 2018;14(AB):AB101–AB111.
■ IMAGING GUIDELINES AND CHALLENGES

TR requires multimodality imaging with 2D trans-thoracic echocardiography (TTE), 3D TTE, computed tomography (CT), and magnetic resonance imaging (MRI). While TTE and transesophageal echocardiography (TEE) are excellent at visualizing the tricuspid valve leaflets, CT and MRI are superior for accurate assessment of the tricuspid annulus geometry (Figures 2 and 3).

The first step to imaging the tricuspid valve is invariably 2D TTE. TTE can distinguish the etiology of TR, quantify its severity, and determine the annular dimensions. Some argue that the traditional classification of TR has limitations and the definition of severe TR is broad, thus a new classification has been proposed: mild, moderate, severe, massive, and torrential. Better classification of TR can potentially help clinicians identify patients who would benefit from transcatheter valve therapies. Similarly, a staging system has also been proposed for functional TR (Table 1) based on annular dilation, RV function, remodeling, TR severity, leaflet coaptation, and right-sided heart failure.

Significant annular dilation on TTE is defined as diastolic diameter greater than 40 mm or greater than 21 mm/m². Simultaneous assessment of all 3 leaflets can be challenging; thus, different projections are useful (long-axis RV inflow, short-axis at the aortic valve, apical 4-chamber view, and subcostal views). Despite this, the designation of individual leaflets of the tricuspid valve should be done with caution unless all 3 leaflets can be seen simultaneously. Real-time 3D TTE proves to be useful in situations where this is not possible and allows, through its ability to obtain a short-axis view of the tricuspid valve, simultaneous visualization of all 3 leaflets moving during the cardiac cycle. It also allows visualization of their commissures and attachment to the tricuspid annulus. 3D TTE can also be used to assess RV volumes; however, wherever available, cardiac MRI is the gold standard for assessing RV function and volumes. The American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend 3D TTE or MRI for evaluation of RV systolic function and RV volumes in patients with severe TR and suboptimal TTE (Class IIb, level of evidence C). CT offers in-depth assessment of various dimensions relevant to

### TABLE 2

<table>
<thead>
<tr>
<th>Central jet area</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Massive</th>
<th>Torrential</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt; 5 cm²</td>
<td>5–10 cm²</td>
<td>&gt; 10 cm²</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vena contracta (biplane)</td>
<td>&lt; 3 mm</td>
<td>3–6.9 mm</td>
<td>7–13 mm</td>
<td>14–20 mm</td>
<td>≥ 21 mm</td>
</tr>
<tr>
<td>EROA (PISA)</td>
<td>&lt; 20 mm²</td>
<td>20–39 mm²</td>
<td>40–59 mm²</td>
<td>60–79 mm²</td>
<td>≥ 80 mm²</td>
</tr>
<tr>
<td>Vena contracta width</td>
<td>Not defined</td>
<td>&lt; 0.70 cm</td>
<td>&gt; 0.70 cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuous wave jet density and contour</td>
<td>Soft and parabolic</td>
<td>Dense and variable</td>
<td>Dense, triangular with an early peak</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic vein flow</td>
<td>Systolic dominance</td>
<td>Systolic blunting</td>
<td>Systolic reversal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac chambers and IVC</td>
<td>Normal size of RA/RV/IVC</td>
<td>No RV enlargement, no or mild RA enlargement, no or mild IVC enlargement with diastolic intraventricular septum flattening. Reduced RV systolic function in late phase.</td>
<td>RV/RA/IVC dilated with decreased IVC and reduced RV systolic function. Elevated RV pressure. Diastolic intraventricular septum flattening. Reduced RV systolic function in late phase.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3D VCA = three-dimensional vena contracta area; EROA = effective regurgitant orifice area; IVC = inferior vena cava; PISA = proximal isovelocity surface area; RA = right atrium; RV = right ventricle
the tricuspid valve. This includes the dimensions of the RV, tricuspid valve annulus, and the annular distance from the RV apex. The venous anatomy and dimensions of the subclavian and axillary veins can guide access-site selection. The appropriate fluoroscopic angles for valve deployment can be derived from the CT. CT can also detect the course of the right coronary artery to the tricuspid annulus, and a course of 2 mm or less is considered high risk, which is a common finding in about 40% of patients with severe TR.

**Management of functional TR**

Based on the 2014 ACC/AHA guidelines for valvular heart disease, grading of TR is done based on the central jet area, vena contracta width, continuous jet density and contour, and hepatic vein flow. Table 2 details the stages of TR based on these guidelines. The guidelines recommend the use of diuretics in severe TR and signs of right-sided heart failure (Class IIa, level of evidence C). Medical therapies to reduce elevated pulmonary artery pressures or pulmonary vascular resistance or both are also recommended in severe functional TR (Class IIb, level of evidence C, D). Table 3 displays a comparison of ACC/AHA guidelines (2014) and the European Society of Cardiology (2017) guidelines for surgical management of functional TR.

**Patient selection**

Timely referral to a tertiary center is essential to achieve an optimal result after transcatheter tricuspid valve intervention. Functional TR is a common sequela of previous or current severe left-sided heart disease. The concept that surgical or percutaneous management of left-sided disease leads to spontaneous resolution of TR is a misconception. Concomitant treatment of TR and left-sided disease should always be considered during the index procedure. From the surgical literature, some of the predictors for recurrence of TR are tethering distance greater than 76 mm, mitral valve replacement, pulmonary artery pressure of over 90 mm Hg, severe RV impairment, left ventricular dysfunction and advanced left ventricular remodeling, intracardiac devices, and suture annuloplasty. Patients with severe pulmonary hypertension and RV dysfunction do not tolerate a precipitous reduction in TR and can develop acute afterload mismatch and decompensation.

---

**Table 3**

Guidelines for the management of functional tricuspid regurgitation

<table>
<thead>
<tr>
<th>American College of Cardiology/American Heart Association (2014)</th>
<th>European Society of Cardiology (2017)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Tricuspid valve surgery is recommended for patients with severe tricuspid regurgitation (stages C and D) undergoing left-sided valve surgery (Class I, level of evidence C).</td>
<td>• Surgery is indicated in patients with severe secondary tricuspid regurgitation undergoing left-sided surgery (Class I, level of evidence C).</td>
</tr>
<tr>
<td>• Current guidelines provide for tricuspid valve repair in patients with mild, moderate, or greater functional tricuspid regurgitation at the time of left-sided surgery with either tricuspid annular dilation or prior evidence of right heart failure (Class IIa, level of evidence B).</td>
<td>• Surgery is indicated in patients with mild or moderate secondary tricuspid regurgitation with a dilated annulus (≥ 40 mm or &gt; 21mm/m² by 2-dimensional transthoracic echocardiography) undergoing left-sided surgery (Class IIa, level of evidence C).</td>
</tr>
<tr>
<td>• Tricuspid valve repair may be considered for patients with moderate functional tricuspid regurgitation and pulmonary hypertension at the time of left-sided surgery (Class IIb, level of evidence C).</td>
<td>• Surgery may be considered in patients undergoing left-sided surgery with mild or moderate secondary tricuspid regurgitation even in the absence of annular dilation when previous right-sided heart failure has been documented (Class IIb, level of evidence C).</td>
</tr>
<tr>
<td>• Reoperation for isolated tricuspid valve repair or replacement may be considered for persistent symptoms due to severe tricuspid regurgitation (stage D) in patients who have undergone previous left-sided valve surgery and who do not have severe pulmonary hypertension or significant right ventricular systolic dysfunction (Class IIb, level of evidence C).</td>
<td>• After previous left-sided surgery and in the absence of recurrent left-sided valve dysfunction, surgery should be considered in patients with severe tricuspid regurgitation who are symptomatic or have progressive right ventricular dilation/dysfunction, in the absence of severe left ventricular/right ventricular dysfunction or pulmonary vascular disease/hypertension (Class IIa, level of evidence C).</td>
</tr>
</tbody>
</table>

---
All the factors mentioned above should be taken into consideration and the severity of TR should not be the primary reason for referral. Multiple staging systems have been proposed recently based on annular dilation, RV function, remodeling, TR severity, leaflet coaptation, and right-sided heart failure.\(^3\)\(^,\)\(^30\)\(^,\)\(^31\) Stages 4 and 5 as listed in Table 1 are not suitable for percutaneous transcatheter tricuspid valve management.

**Percutaneous tricuspid interventions: Devices and outcomes**

Use of transcatheter approaches for the treatment of severe aortic stenosis and mitral regurgitation has led to growing interest in adopting these techniques for severe functional TR. However, challenges to the tricuspid edge-to-edge repair include the trileaflet nature of tricuspid valve, wide malcoaptation gaps, higher chordal density, and fragility of the leaflet and annular tissues. Additionally, the proximity to the conduction system, right coronary artery, and coronary sinus potentially predispose to procedural complications.\(^3\)\(^,\)\(^31\) However, despite these difficulties, there are several reasons to develop and advance novel methods of minimally invasive, percutaneous TR treatment. Medical treatment is restricted to the use of diuretics and can only partially address the symptoms,\(^3\) and TR is associated with poor prognosis both in isolated disease and when associated with left-sided pathology. It is also important to note that patients with TR may have less benefit from percutaneous procedures for mitral regurgitation.\(^34\)\(^,\)\(^35\)

Several devices and strategies are being evaluated for the treatment of functional TR. These can be broadly classified by mechanism into leaflet approximation devices, annuloplasty devices, transcatheter tricuspid valve implantation, and caval valve implantation.

**Leaflet approximation device.** Sixty-four patients from 10 international centers were treated with the MitraClip (Abbott Vascular) for TR. Functional TR was present in 88% of patients. Results showed significant improvements in echocardiographic and functional parameters without any procedural adverse events with the use of the MitraClip device (Figure 4). It is interesting to note that patients who had a combined mitral and tricuspid MitraClip procedure did not have a significant increase in 6-minute walk distance at 30 days. However, there was a similar echocardiographic improvement in patients undergoing tricuspid clipping alone and those undergoing combined mitral and tricuspid clipping.\(^36\)

The multicenter international TriValve (Transcatheter Tricuspid Valve Therapies) registry reported 1-year outcomes after edge-to-edge repair in 249 patients with severe TR.\(^37\) Nearly 90% of the cohort had functional TR and over half the population underwent concomitant treatment of tricuspid and mitral regurgitation. The mean age of the cohort was 77 and the mean European System for Cardiac Operative Risk Evaluation II score was 6.4%. Procedural success was achieved in 77% of the patients (TR reduction to grade ≤ 2+). At 12 months in nearly 70% of the patients there was sustained improvement in TR severity and New York Heart Association functional class (≤ II). Death due to any cause was 20%. The risk factors for procedural failure were the absence of central or anteroseptal TR jet location, effective regurgitant orifice area greater than or equal to 0.70 cm\(^2\), tricuspid coaptation gap greater than 0.65 cm, and tenting area greater than 3.15 cm\(^2\).\(^37\)

The TRILUMINATE trial was a single-arm study of 85 patients with severe functional TR.\(^2\) No periprocedural deaths, myocardial infarctions, or strokes occurred. At 6 months, all-cause mortality was reported in 5% (4 of 84) of patients and the rate of major bleeding was 11% (9 of 84). Single leaflet device attachment was seen in 7% of patients (5 of 72) and tricuspid valve stenosis was noted in 9% of patients (6 of 65).

The PASCAL system (Edwards Lifesciences) consists of a 10-mm central spacer that blocks the regurgitant orifice. It attaches to the leaflets with 2 paddles and was first used in an 82-year-old woman with secondary TR and advanced right-sided heart failure.\(^38\) Two devices were implanted and the patient was discharged at 72 hours. At 1-month follow-up there was a resolution of ascites, and the dose of diuretics was lowered, which was associated with improved quality of life and 6-minute walk distance. The Edwards CLASP TR EFS (NCT03745313) study is evaluating the safety and efficacy of the PASCAL system in patients with severe symptomatic functional or degenerative TR.

**Annuloplasty systems.** Annuloplasty devices recreate surgical techniques and address the primary pathophysiologic mechanism of TR, annular dilation. All annular-based devices require sufficient annular tissue for anchoring and may be prone to dehiscence if tissue quality is poor or excessive force is applied. Therefore,
TRICUSPID REGURGITATION TRANSCATHETER INTERVENTION

they may have limited effectiveness in patients with advanced RV disease and excessive tethering.39

The TriCinch system (4Tech Cardio Ltd.) is a percutaneous device designed for tricuspid remodeling, using a transfemoral fixation of a stainless-steel cork-screw into the anteroposterior tricuspid valve annulus. The corkscrew is connected through a Dacron band to a self-expanding Nitinol stent. By pulling the system towards the inferior vena cava, the anchoring corkscrew remodels the anteroposterior annulus, and the tension is maintained by fixation of the stent in the inferior vena cava. The first use of this device was reported in 2015 for the treatment of functional TR in a 72-year-old woman with right-sided heart failure and repeated decompensations. The patient reportedly had good functional status at 6-month follow-up.40 The TriCinch Coil System was also performed with deliberate creation of pneumopericardium to guarantee the appropriate advancement of the device in a woman age 81 with severe functional TR.41 The PREVENT trial (Percutaneous Tricuspid Valve Annuloplasty System for Symptomatic Chronic Functional Tricuspid Regurgitation) reported a procedural success rate of 94% in 18 patients (≥ 1-grade reduction of TR).42 Two patients developed pericardial tamponade periprocedurally, and leaflet device detachment was noted in 4 patients. Significant improvement in 6-minute walk distance and quality of life was also noted. The safety and efficacy of the TriCinch System is currently being assessed in clinical trials (NCT03294200 and NCT03632967).

Another novel method of reducing functional TR is via plication of the tricuspid annulus using the TriAlign system (Mitralign Inc.) (Figure 5). This system consists of a deflectable guide catheter introduced using a trans-jugular approach to position a wire catheter on the ventricular side of the tricuspid annulus, and then to introduce an insulated radiofrequency wire across the annulus. Thereafter, a pledgeted suture is delivered (using a catheter over the radiofrequency wire) and the process is repeated to insert a second pledget. The sutures are then plicated, leaving behind a bicuspid tricuspid valve with reduced annular dimensions and a regurgitant orifice. Recently, 30-day results from the SCOUT trial (Percutaneous Tricuspid Valve Annuloplasty System for Symptomatic Chronic Functional Tricuspid Regurgitation) were published using this procedure. In a cohort of 15 patients, they showed that there was 80% success without the need for re-intervention.43 The SCOUT II trial, an open-label nonrandomized clinical study, is currently recruiting patients with evidence of functional TR secondary to annular dilation (NCT03225612).

An exciting new development has been the Cardioband (ValtechCardio), which mimics open-heart annuloplasty for TR. It is a transcatheter annuloplasty system designed to implant a Dacron surgical-like adjustable band with a sutureless technique under echocardiographic and fluoroscopic guidance. The device is delivered via the transfemoral approach and is secured with 17 anchors on the atrial side of the anterior and tricuspid annulus. The first reported use in humans was published in early 2017 in a patient with functional TR and annular dilation who underwent the procedure successfully. The TRI-REPAIR study consisted of 30 patients undergoing Cardioband for moderate to severe functional TR.44 The average age of participants was 75 and most were women. Procedural success was 100%, with a substantial decrease in annular septolateral diameter, effective regurgitant orifice area, and vena contracta width at 6 months. Similar results were reported by the Cardioband TR EFS Investigators in 22 patients (NCT03382457). The cohort consisted of mostly women (77%) with a mean age of 78. Atrial fibrillation and flutter were common comorbidities, with a 96% prevalence rate, and the procedural success rate was 95%. Complications included 1 right-sided coronary artery constriction, and 7 patients suffered a major bleeding event. There was no cardiovascular mortality, myocardial infarction, or stroke.

Another device in the investigation phase for tricuspid repair is the minimally invasive annuloplasty (MIA) technology (Micro Interventional Devices, Inc.). Two patients in Lithuania received this device.
with no intraoperative complications, based on media reports. The Study of Transcatheter Tricuspid Annular Repair (STTAR) is a multicenter safety and performance study being conducted in Europe to evaluate the use of this device.46

A new device under development is the Millipede system (Millipede Inc.), which is an adjustable, semirigid ring attached to the annulus by rotational anchors positioned at defined intervals. The device has a zigzag appearance like the top of a crown, with the anchors at the lowest points and a collar around the hinge points at the crests. The annular reduction is then accomplished by repositioning the collars further down the crest, effectively reducing the distance between the anchors.47 The pledget-assisted suture tricuspid annuloplasty (PASTA) device mirrors the Hetzer double-orifice suture procedure.48 The first in human experience resulted in annular dehiscence of the device 2 days after its insertion and this device potentially should be not be used in large friable annuli.48

Transcatheter tricuspid valve implantation. The Gate valve (NaviGate Cardiac Structures Inc.) is an atrioventricular valved stent that has been developed for the treatment of TR (Figure 6). The first reported use in humans of this catheter-guided tricuspid atrioventricular valved stent was at Cleveland Clinic in a 64-year-old woman with multiple comorbidities including end-stage renal disease and multiple prior admissions for right-sided heart failure. The tricuspid annulus measured 50 mm × 40 mm on a focused 4D CT study. The patient tolerated the implantation well and was transferred to the ICU. Although she had a prolonged hospital course, she was discharged on postoperative day 29. The predischarge TTE for this patient showed moderate to severe RV dysfunction and mild to moderate TR, and paravalvular leak. The second patient was a 78-year-old man with significant cardiac history including coronary artery disease, previous myocardial infarction, atrial fibrillation, and 3 prior open-heart surgeries for coronary bypass, mitral valve repair, and 2 tricuspid valve repairs (annuloplasty ring 34 mm). He had a progressive decline in functional capacity due to right-sided heart failure that was refractory to medical treatment. He was discharged successfully on postoperative day 7, and predischarge TTE showed severe RV dysfunction and mild paravalvaral TR. Both of these patients were deemed to be at prohibitive risk of open-heart surgery by a multi-disciplinary team.49

Caval aortic valve implantation (CAVI). Heterotopic tricuspid valve implantation is a potential option in patients with severe TR and significant venous congestion. The valve in this technique is inserted percutaneously into the inferior vena cava to protect the abdominal vasculature from elevated venous pressures and systolic backflow from severe TR. The upper valve segment protrudes into the right atrium, and the lower segment anchors to the inferior vena cava. The first reported experience with CAVI was reported by Lauten and colleagues in 2011.50 The valve implantation was successful, and the patient’s functional capacity and heart failure symptoms improved. Right atrial volume overload and right atrial ventricularization are potential demerits of CAVI.51

The Treatment of Severe Secondary Tricuspid Regurgitation in Patients With Advance Heart Failure With Caval Vein Implantation of the Edwards Sapien XT Valve (TRICAVAL) trial consisted of 28 patients with severe symptomatic TR that were randomized to optimal medical therapy or Edwards Sapien XT valve implantation (NCT02387697).52 There was no difference noted in functional end points (6-minute walk test, RV function, hospitalizations, and quality of life) across the intervention and control arms. TRICAVAL was cancelled due to safety concerns. The Heterotopic Implantation of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior Vena Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)(54) trial is currently evaluating the feasibility of this device53 (NCT02339974).

Device-lead-induced TR

Patients with device-lead-induced TR are a special subgroup. The reported incidence of lead-induced TR is as high as 45%54,55 and is linked to a poor prognosis.56 It has been postulated that this is caused by bulky leads and apical lead placement and that the leads also alter the RV geometry resulting in TR.57,58 TR can also be a result of leaflet perforation during lead placement. Other mechanisms include lead impingement or adherence and lead entrapment in the subvalvular apparatus of the tricuspid valve. Imaging can be challenging, and the severity of lead-induced TR is often underestimated.59 Newer imaging tools like calculation of regurgitant fractions and volumes based on 3D data sets could potentially overcome this challenge. Percutaneous transcatheter tricuspid interventions for lead-induced TR have been investigated using various devices including
MitralClip, FORMA, TriCinch, Trialign, Cardioband, NaviGate, and CAVI.\textsuperscript{54} There is a risk of lead damage after device implantation and potentially impedes future lead extraction in case of lead endocarditis.\textsuperscript{60}

## FUTURE TRIALS

Several clinical trials of new devices for TR are currently under way (Table 4). To date, clinical trials have been done in patients with advanced stages of functional TR and there is an absence of a standard definition of clinical and imaging outcomes. Ideal trial design should include patients without RV dysfunction, remodeling, and right-sided heart failure that are randomized to surgical management or percutaneous intervention. The lack of specific clinical symptoms relevant to tricuspid valve disease and heavy reliance on quantitative assessment of TR, annular dilation, and RV size and function as imaging end points pose significant challenges for device approval. Important exclusion criteria should include severe pulmonary hypertension, severe RV failure, and other significant comorbidities (frailty, advanced kidney disease, liver dysfunction, severe lung disease). Another consideration could be given to a prospective registry of concomitant percutaneous mitral and tricuspid intervention for severe functional mitral regurgitation. Long-term preservation of RV function and preventing TR progression after tricuspid intervention could be demonstrated in such a cohort.

### TABLE 4
Clinical trials investigating the use of new devices for tricuspid regurgitation

<table>
<thead>
<tr>
<th>Device</th>
<th>Clinical trial (NCT#)</th>
<th>Primary endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tricuspid valve repair system (Abbott Medical Devices)</td>
<td>TRILUMINATE (NCT03227757)</td>
<td>Tricuspid regurgitation reduction ≥ 1 grade at 1 month</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Composite of major adverse events at 6 months</td>
</tr>
<tr>
<td>PASCAL (Edwards Lifesciences)</td>
<td>Edwards CLASP TR EFS (NCT03745313)</td>
<td>Freedom from device or procedure-related adverse events at 1 month</td>
</tr>
<tr>
<td>TriCinch system (4Tech Cardio Ltd.)</td>
<td>PREVENT (NCT02098200)</td>
<td>Safety: The percentage of participants with major adverse events within 30 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Performance: The reduction in the degree of tricuspid regurgitation measured</td>
</tr>
<tr>
<td></td>
<td></td>
<td>immediately after the procedure compared with baseline</td>
</tr>
<tr>
<td>Clinical Trial Evaluation of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System (NCT03294200)</td>
<td></td>
<td>All-cause mortality at 1 month</td>
</tr>
<tr>
<td>TriAlign (Mitraign Inc.)</td>
<td>PTVAS (SCOUT-II) (NCT03225612)</td>
<td>Incidence of all-cause mortality at 30 days</td>
</tr>
<tr>
<td>Cardioband (ValtechCardio)</td>
<td>TRI-REPAIR (NCT02981953)</td>
<td>The overall rate of major serious adverse events and serious adverse device</td>
</tr>
<tr>
<td></td>
<td></td>
<td>effects at 30 days.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Successful access, deployment and positioning of the Cardioband device and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>septolateral dimension reduction intraprocedurally. Change in septolateral</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dimension at 30 days.</td>
</tr>
<tr>
<td>Edwards Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study (NCT03382457)</td>
<td>Freedom from device or procedure-related adverse events at 30 days.</td>
<td></td>
</tr>
<tr>
<td>MIA (Micro Interventional Devices Inc.)</td>
<td>STTAR (NCT03692598)</td>
<td>Safety: Major adverse event at 1 month</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Performance: The technical success rate of MIA implant and reduction in the valve area</td>
</tr>
</tbody>
</table>

MIA = minimally invasive annuloplasty; PREVENT = Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System; PTVAS = Performance of the TriAlign Percutaneous Tricuspid Valve Annuloplasty System; TRILUMINATE = Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System; TRI-REPAIR = Tricuspid Regurgitation Repair With Cardioband Transcatheter System; STTAR = Study of Transcatheter Tricuspid Annular Repair

Source: Data from clinicaltrials.gov
CONCLUSION

Functional TR is a common valvular heart disease that is often overlooked and is linked to a poor prognosis. There are numerous percutaneous and minimally invasive options under different stages of investigation. The published data so far on percutaneous therapies demonstrate promising results in the form of a reasonable reduction in TR along with substantial improvement in the quality of life. The transcatheter device technology is currently evolving for the tricuspid valve. The evidence base in this intervention is growing rapidly; however, it is far behind its aortic counterpart. To improve the existing technology, it is imperative to understand tricuspid valve anatomy using multimodality imaging to identify patients early and prevent irreversible RV failure. Patient selection based on anatomy for the appropriate device technology (ie, coaptation vs annuloplasty vs replacement) is imperative. Improved device technology best matched to patient factors is likely to increase the array of options available to patients for TR.

REFERENCES


TRICUSPID REGURGITATION TRANSCATHETER INTERVENTION


42. Gray W; for the Cardioband TR EF Investigators. Results from the early feasibility study of cardioband tricuspid system for functional tricuspid regurgitation. Presented at: Transcatheter Valve Therapies (TVT 2017), a Cardiovascular Research Foundation Meeting; September 24–28, 2019; San Francisco, CA. TCT93.


A practical approach to the cholesterol guidelines and ASCVD prevention

■ ABSTRACT

Lifestyle factors remain the bedrock of atherosclerotic cardiovascular disease (ASCVD) prevention. Statins remain the first-line therapy for primary and secondary prevention of ASCVD. Physicians are encouraged to discuss the risks and benefits of statins with patients before beginning therapy. Nonstatins and proprotein convertase subtilisin-kexin type 9 inhibitors are recommended for secondary prevention in patients with clinical ASCVD. For patients at intermediate risk of ASCVD, new risk-enhancing factors, including chronic inflammatory conditions and ethnicity, should be considered to better risk stratify these patients.

■ KEY POINTS

Lifestyle factors are the cornerstone of preventing ASCVD.

High low-density lipoprotein cholesterol (LDL-C) levels warrant intervention.

Statins are the first-line therapy for lowering LDL-C and preventing ASCVD.

Calcium score and risk-enhancing factors help stratify risk in patients of intermediate risk.

Nonstatin agents are warranted in patients not achieving LDL-C reduction goals despite maximum statin therapy or in primary prevention for patients at very-high risk and not achieving LDL-C reduction goals.

■ INTRODUCTION

Maintaining healthy cholesterol levels is essential to primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). High cholesterol raises the risk of heart disease, which is the leading cause of death in the United States. Just over 50% of US adults who would benefit from cholesterol-lowering medication are taking it.

■ 2018 CHOLESTEROL GUIDELINES

The recent 2018 cholesterol guidelines for prevention of ASCVD again stress the importance of lifestyle and role of statins as first-line therapy in primary and secondary prevention. The guidelines affirm the need to aggressively treat patients with high cholesterol and particularly patients at high risk of ASCVD.

Table 1 highlights key updates to the cholesterol guidelines with respect to a clinician-patient risk discussion before beginning statins, tailoring treatment using a more extensive list or risk modifiers, additional testing for patients of intermediate risk, and use of nonstatin agents in secondary prevention.

■ WHAT REMAINS THE SAME

Like the 2013 cholesterol guidelines, the new 2018 guidelines stress lifestyle, such as diet and exercise, statin therapy as the first-line drug for treating for atherosclerosis risk reduction, and risk assessment using the Pooled Cohort Equation in primary prevention of ASCVD.

Lifestyle: Cornerstone of ASCVD prevention

Lifestyle factors such as tobacco cessation, diet, exercise, weight management, and blood pressure management remain the cornerstone of primary and secondary prevention of ASCVD. A healthy diet that ensures the best nutritional value for caloric intake is recommended, such as a Mediterranean-style diet including whole grains and limiting red meat.

Unfortunately, the reality is that the lifestyle of very few Americans meets the lifestyle factor guide-
The average American gets about 16 grams of fiber a day as opposed to the recommended 30 grams. Total animal consumption per capita in the United States has steadily increased and currently stands at 225 pounds of meat.

For exercise, the American Heart Association recommends 30 minutes or more of moderate-intensity aerobic activity at least 5 days a week and high-intensity strengthening at least 2 days a week. As with diet, Americans fall short of exercise recommendations with 39% considered sedentary, 60% get no regular exercise, and of those who exercise, 80% are not exercising effectively. Rates of sedentary lifestyle also increase with age.

These data are clear that most patients do not meet lifestyle recommendations for diet and exercise to prevent ASCVD.

### Patient factors that warrant treatment

As stated, adherence to a healthy lifestyle is the primary prevention of ASCVD for all patients (Figure 1). Treatment to maintain healthy cholesterol and prevent cardiovascular disease is warranted in patients who have had clinical ASCVD (Figure 2); for everyone else, treatment is based on a calculation of risk, including other conditions such as hypercholesterolemia and diabetes:

- Primary hypercholesterolemia (low-density lipoprotein cholesterol [LDL-C] > 190 mg/dL)
- Diabetes and age 40 to 75
- Others factors based on calculated risk (Pooled Cohort Equation, coronary artery calcium [CAC], risk-enhancers)
- ASCVD including myocardial infraction, coronary artery disease, percutaneous coronary intervention/coronary artery bypass grafting, other arterial revascularization, transient ischemic attack, and stroke.

**High LDL-C warrants statin therapy.** In addition to unfavorable lifestyle factors, high LDL-C is a known risk factor for ASCVD and it warrants intervention. Regardless of age, patients with LDL-C greater than 190 mg/dL should be started on a statin therapy. The latest guidelines now encourage a discussion of ASCVD risk between the clinician and patient before beginning statin therapy.

The selection and use of statin therapy is based on the LDL-C reduction goals as discussed below.

**Calculated risk.** In the absence of prior ASCVD, determining a patient’s 10-year risk of ASCVD starts with a risk calculation such as the Pooled Cohort Equation. Risk calculation is based on age, sex, race, blood pressure, cholesterol, tobacco use, history of diabetes, and treatment with a statin or aspirin or for hypertension. A result of 5% to 7.4% indicates moderate 10-year risk of ASCVD and 7.5% or greater indicates a high 10-year risk (http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#1/calculate/estimate/).

For patients with a calculated risk of ASCVD in the moderate range, the new guidelines contain several new important risk enhancers to consider, as discussed below.

### WHAT IS NEW

In addition to a patient-physician discussion before beginning statins, the biggest changes in the new
cholesterol guidelines relate to identifying patients at intermediate risk of ASCVD and how best to stratify their level of risk.

**Intermediate risk**
The 2018 guidelines recommend new tools to further stratify patients at intermediate risk for ASCVD using CAC scoring and other new risk-enhancing factors.

**CAC scoring.** CAC score measures the amount of calcium in the artery walls of the heart and arterial plaque and can help further stratify patients with an intermediate risk for ASCVD. For patients at moderate risk and unsure about use of statin therapy, a CAC score may help inform risk-benefit treatment decisions. A CAC score of:

- A 0 indicates lower risk and favors continued dietary and lifestyle modifications and no statin therapy unless diabetes, family history of premature coronary heart disease, or cigarette smoking are present
- 1 to 99 indicates elevated risk and favors use of statin therapy especially after age 55
- 100 or greater or the 75th percentile or greater, indicates the need to initiate statin therapy.

**Risk-enhancing factors.** The latest cholesterol guidelines include an extensive list of risk-enhancing factors (Table 2). Family history is a risk factor, as in the past, in addition to metabolic disease, primary hypercholesterolemia, and chronic kidney disease.

Notably, chronic inflammatory conditions, such as psoriasis, rheumatoid arthritis, and lupus, are now considered risk-enhancing factors. Research indicates that autoimmune disease increases the risk for atherosclerosis by 300% to 500%.

The risk factors related to autoimmune disease are particularly relevant to women because

---

**Figure 1.** Primary prevention for atherosclerotic cardiovascular disease (ASCVD).

LDL-C = low-density lipoprotein cholesterol

---

**Table 2.** Risk-enhancing factors for ASCVD.

<table>
<thead>
<tr>
<th>Risk-enhancing Factor</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family history of premature ASCVD or LDL-C ≥ 160 mg/dL</td>
<td>Indicates need for statin therapy</td>
</tr>
<tr>
<td>Metabolic disease, primary hypercholesterolemia, and chronic kidney disease</td>
<td>Indicates need for statin therapy</td>
</tr>
<tr>
<td>Chronic inflammatory conditions, such as psoriasis, rheumatoid arthritis, and lupus</td>
<td>Indicates need for statin therapy</td>
</tr>
</tbody>
</table>

---

**Source:** Data from reference 4.
80% of autoimmune disease occurs in women. Additional risk enhancers unique to women are premature menopause, menopause before the age of 40 regardless of whether surgically or naturally, preeclampsia, gestational diabetes, and polycystic ovary syndrome.

Another novel factor included in the new guidelines is high-risk ethnicity among South Asians. Lipid and biomarker factors include high-sensitive C-reactive protein, lipoprotein(a), apolipoprotein B, and ankle-brachial index. Lipoprotein(a) is a genetic disorder occurring in 20% of the population and it increases the risk of early MI and stroke. A randomized, phase 3 trial in 8,000 patients of an antisense oligonucleotide drug for cardiovascular disease and lipoprotein(a) is underway (NCT04023552 available at clinicaltrials.gov).

The new extensive list of risk enhancers should be considered to risk stratify and tailor treatment in patients with an intermediate risk of ASCVD.

Very high risk/secondary prevention: Nonstatins and PCSK9 inhibitors

Finally, there is new guidance about the role of nonstatin agents, such as ezetimibe and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, in secondary prevention. Very high risk of ASCVD exists in patients with a clinical history of a major atherosclerotic event, recent ASCVD, myocardial infarction, or ischemic stroke. These high-risk patients should have an LDL-C less than 70 mg/dL, though the Endocrine Society recommends LDL-C less than 55 mg/dL in patients diabetes and high-risk features for ASCVD.

There are 3 nonstatin drugs currently available for LDL-C reduction (Table 3). Ezetimibe is a cholesterol absorption inhibitor shown to lower LDL-C by 18% taken as monotherapy and 25% taken as combination therapy.

The 2 available PCSK9 inhibitors, alirocumab and evolocumab, inhibit LDL-C receptors from breaking...
A very interesting finding about PCSK9 inhibitors is that unlike statins, no matter how low LDL-C levels go, there is no increased in the risk of diabetes.\textsuperscript{13} Reduction of LDL-C is reportedly similar at 45% to 58% for alirocumab and 58% to 64% evolocumab depending on the dose.\textsuperscript{4}

A very interesting finding about PCSK9 inhibitors is that unlike statins, no matter how low LDL-C levels go, there is no increased in the risk of diabetes.\textsuperscript{13}

Important updates to the 2018 cholesterol guidelines include an emphasis on a risk-benefit discussion between the clinician and patient before beginning statin therapy. Statins remain the first-line drugs for lowering cholesterol and ASCVD risk reduction. The type of statin and dose depends on the intensity or degree of reduction of LDL-C desired (Table 4).

**SUMMARY**

With so much awareness and talk about the importance of cholesterol, many have the false impression that patients are being over treated for it. In fact, a very small percentage of patients take 2 lipid-lowering drugs and much of the patient population at high risk for ASCVD is not under control, especially women. The data are robust that patients at high clinical risk for ASCVD should be treated aggressively. For patients at intermediate risk, calcium scoring and attention to risk-enhancing factors can help stratify ASCVD risk, as well as present an opportunity for discussion and shared decision-making.
CHOLESTEROL AND CV DISEASE PREVENTION

TABLE 4
Statin therapy for reduction of LDL-C

<table>
<thead>
<tr>
<th>Drug</th>
<th>Intensity of LDL-C reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>High (&gt; 50%)</td>
</tr>
<tr>
<td>Atorvastatin (Lipitor)</td>
<td>40 mg/80 mg, daily</td>
</tr>
<tr>
<td>Rosuvastatin (Crestor)</td>
<td>20 mg/40 mg, daily</td>
</tr>
<tr>
<td>Simvastatin (Zocor)</td>
<td>20 mg/40 mg, daily</td>
</tr>
<tr>
<td>Pravastatin (Pravachol)</td>
<td>40 mg/80 mg, daily</td>
</tr>
<tr>
<td>Pitavastatin (Livalo)</td>
<td>1 mg to 4 mg, daily</td>
</tr>
<tr>
<td>Lovastatin (Mevacor, Altoprev)</td>
<td>40 mg/80 mg, daily</td>
</tr>
<tr>
<td>Fluvastatin XL (Lescol XL)</td>
<td>80 mg, daily</td>
</tr>
<tr>
<td>Fluvastatin (Lescol)</td>
<td>40 mg, twice daily</td>
</tr>
</tbody>
</table>

LDL-C = low-density lipoprotein cholesterol

REFERENCES


Correspondence: Leslie Cho, MD, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, JB1, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195; choi@ccf.org
New treatments for peripheral artery disease

ABSTRACT

The stenosis or occlusion of extremities defining peripheral artery disease (PAD) is a risk factor for adverse cardiovascular events and adverse limb events including amputation. PAD is common, can occur without symptoms or with claudication, and is easily diagnosed. Proper diagnosis and adherence to guideline-directed therapy can reduce the morbidity and potential mortality associated with PAD.

KEY POINTS

PAD is stenosis or occlusion of the upper or lower extremities caused by atherosclerotic plaque.

PAD is common, often overlooked because it is frequently asymptomatic, but easily diagnosed by obtaining an ankle-brachial index.

Management and medical therapies for PAD include lifestyle measures, optimal blood pressure and cholesterol control, antithrombotic agents to manage the risk of thrombotic events, and claudication therapy.

INTRODUCTION

Peripheral artery disease (PAD) is characterized by stenosis or occlusion of the arteries of the upper or lower limbs due to atherosclerotic plaque in the vessel walls. PAD is common but often overlooked. A public awareness survey found 74% of respondents (N = 2,501) were not aware of PAD. Unfortunately, many physicians also lack awareness of PAD or fail to consider it when evaluating patients.

PAD is easily diagnosed in any office setting by obtaining an ankle-brachial index, which is the ratio calculated by the measured lower extremity (ankle) systolic pressure divided by the brachial artery (arm) systolic pressure. An ankle-brachial index of 0.91 to 1.4 is normal, 0.90 or less is diagnostic for PAD, and less than 0.40 is diagnostic for severe PAD. Patients may experience leg pain (claudication), rest pain, or leg ulcerations. The ankle-brachial index is 95% sensitive and 99% specific for PAD. With greater awareness and screening for PAD, significant patient morbidity can be avoided.

EPIDEMIOLOGY AND PATHOPHYSIOLOGY

Over 200 million people worldwide have PAD and it occurs in men and women equally. The prevalence of PAD increases with age occurring in about 30% of people over 70 and in people 50 to 69 with diabetes or those who smoke. Both mortality and disability from PAD have increased over the last several decades. Patients with PAD are at high risk for major adverse cardiovascular events and major adverse limb events, the most dreaded complication being amputation.

SIGN AND SYMPTOMS

Failure to recognize PAD is largely due to the absence of symptoms. In the ambulatory setting, about 50% of individuals with PAD have no leg symptoms whatsoever. Only about 15% of those with PAD have typical claudication, 30% have atypical limb symptoms, and about 3% have critical limb ischemia.

The 5-year outcome for patients with PAD includes stable claudication in 70% to 80% of patients; 10% to 20% will require lower extremity revascularization,
and about 1% to 2% will go on to have chronic limb ischaeas (Table 1). Amputation rates are as high as 25% in patients with chronic limb ischemia. It is important to note that for patients with PAD, 20% will have a myocardial infarction or stroke, and death can occur in 15% to 30% over a 5-year period. As these data make clear, PAD is not a benign condition.

Medical therapies and management

As stated, PAD is routinely underdiagnosed but even with proper diagnosis, patients with PAD are less frequently treated with guideline-directed therapies compared with patients with coronary artery disease. Medical therapies for, and the management of PAD revolve around preventing myocardial infarction, stroke, and death; improving function and quality of life; and protecting the feet to avoid and prevent amputation.

Diet, exercise, tobacco cessation

Patients with PAD should be counseled about maintaining a healthy diet, exercise, and complete cessation of tobacco use. Recommended exercise programs for patients with PAD have been established and are covered services for older patients by US Centers for Medicare & Medicaid Services. A 12-week supervised treadmill exercise program consists of 3 weekly sessions that begin at 15 minutes and increase to 45 to 50 minutes a session. A home-based walking exercise program or a supervised ergometry exercise program are also recommended and may be better suited to some patients.

Medical therapy

In addition to lifestyle measures, medical therapies for PAD should be employed to:

- Optimize blood pressure preferably using an angiotensin-converting-enzyme inhibitor
- Lower and maintain low-density lipoprotein cholesterol (LDL-C) to less than 70 mg/dL using a statin, ezetimibe, or a proprotein convertase subtilisin-kexin 9 inhibitor or combination.
- Manage risk of thrombotic events with antithrombotic agents such as aspirin, clopidogrel, ticagrelor, vorapaxar, and rivaroxaban
- Treat claudication pain in the extremities with cilostazol if no heart failure.

Several major clinical trials have evaluated antithrombotic agents in patients with PAD, especially symptomatic PAD (Table 2). Among these trials, Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) evaluated cardiovascular outcomes in 27,395 patients including 27% with PAD. Patients received 2.5 mg rivaroxaban twice daily plus 100 mg aspirin, or 5 mg rivaroxaban twice daily, or 100 mg aspirin daily. The cardiovascular outcomes in patients with stable atherosclerotic vascular disease were more favorable in the rivaroxaban-plus-aspirin cohort (hazard ratio = 0.76; 95% confidence interval [CI] 0.66–0.86; P = .001) compared with the rivaroxaban-alone cohort (hazard ratio = 0.90; 95% CI 0.79–1.03; P = .12), but more major bleeding events occurred in patients on rivaroxaban plus aspirin (3.1%) compared with rivaroxaban alone (1.9%). The secondary composite outcome of ischemic stroke, myocardial

### Table 1
Natural history of peripheral artery disease

<table>
<thead>
<tr>
<th>Symptoms at diagnosis in patients with PAD</th>
<th>Patients (%)</th>
<th>5-Year outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic</td>
<td>20–50</td>
<td>Major adverse limb events</td>
</tr>
<tr>
<td>Atypical leg discomfort</td>
<td>40–50</td>
<td>Stable claudication: 70%–80%</td>
</tr>
<tr>
<td>Claudication</td>
<td>10–30</td>
<td>Lower extremity revascularization: 10%–20%</td>
</tr>
<tr>
<td>Critical limb ischemia</td>
<td>1–2</td>
<td>Critical limb ischemia: 1%–2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Major adverse cardiovascular events</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Myocardial infarction/stroke: 20%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Death: 15%–30%</td>
</tr>
</tbody>
</table>

1-year outcomes

- Amputation: 25%

Source: Data from reference 6.
infarction, acute limb ischemia, or cardiovascular death also favored rivaroxaban-plus-aspirin therapy, with emphasis on screening for bleeding.

Figure 1 outlines a frequently used approach to antithrombotic therapy showing that all patients with symptomatic PAD should receive aspirin or clopidogrel or aspirin with rivaroxaban. In patients with asymptomatic PAD, aspirin should be considered especially if disease is present in another vascular bed.

Summary of risk reduction therapy for patients with PAD
The American College of Cardiology/American Heart Association 2016 guidelines on the management of patients with lower extremity PAD advise that reduction of risk for major adverse limb events should include healthy lifestyle modifications, tobacco cessation, achieving target blood pressure goals, glucose lowering therapy, LDL-C lowering using a statin or ezetimibe or a PCSK9 agent, and antiplatelet therapy.

The Further Cardiovascular Outcomes Research With PCSK8 Inhibition in Subjects With Elevated Risk (FOURIER) trial provides insight into LDL-C levels and outcomes in patients with PAD. Of the 27,564 patients in the FOURIER trial, 13.2% had PAD and by lowering LDL-C to a median of 31 mg/dL in patients with symptomatic PAD, major adverse cardiovascular events and major adverse limb events were reduced significantly. Evolocumab plus a statin to reduce LDL-C levels reduced the risk of major adverse limb events (ie, limb ischemia or loss of limb) by 42% in 2 study populations.

For some patients with more advanced disease, aspirin together with rivaroxaban (2.5 mg twice daily) or ticagrelor (60 mg twice daily) or clopidogrel (75 mg once daily) with or without vorapaxar (2.08 mg once daily) is appropriate. Claudication therapy with cilostazol (100 mg twice daily) can be used for patients without heart failure.
Figure 1. Therapeutic approach for patients with peripheral artery disease.

BID = 2 times per day; MI = myocardial infarction


REFERENCES


23. Following Cardiovascular Outcomes Research With PCSK9 Inhibition (FOURIER Trial) investigators: a randomized trial with or without aspirin in patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO Trial. Eur J Prev Cardiol 2015; 22(6):734–742. doi:10.1077/2047487314533215


Correspondence: John Bartholomew, MD, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, ST20, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; Barthoj@ccf.org